Growth Stage

A better way of breast imaging

A better way of breast imaging


Raised to Date: Raised: $583,204

Total Commitments ($USD)



Start Date


Close Date


Min. Goal
Max. Goal
Min. Investment


Security Type

Equity - Common


Series C

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share


Pre-Money Valuation


Rolling Commitments ($USD)

Reporting Date


Days Remaining
% of Min. Goal
% of Max. Goal
Likelihood of Max
Avg. Daily Raise


# of Investors


Create a free account today to gain access to KingsCrowd analytics.
Year Founded



Healthcare & Pharmaceuticals

Tech Sector


Distribution Model




Capital Intensity



Norcross, Georgia

Business Type


Koning, with a valuation of $230 million, is raising funds on StartEngine. The company has developed a revolutionary breast imaging technology that offers real isotropic 3D imaging. The Koning Breast CT creates high-contrast 3D breast images with high spatial resolution without the painful compression of mammograms. Koning has received approvals from FDA PMA, CFDA, CE Mark, and other global regulators and is designed for highly accurate early detection of breast cancer. Dr. Ruola Ning founded Koning in January 2002. The current crowdfunding campaign has a minimum target of $9,997.33 and a maximum target of $2,898,855.85. The campaign proceeds will be used for growth and expansion.

Summary Profit and Loss Statement

Most Recent Year Prior Year












Net Income



Summary Balance Sheet

Most Recent Year Prior Year




Accounts Receivable



Total Assets



Short-Term Debt



Long-Term Debt



Total Liabilities



Financials as of: 07/31/2022
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Koning 12/29/2022 StartEngine $230,180,296 $583,204 Equity - Common Funded RegCF
Koning 01/17/2022 Republic $200,000,000 $2,135,386 SAFE Funded RegCF
Create a free account today to gain access to KingsCrowd analytics.

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Valuation History

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Employee History

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars

Analyst Report Analyst Report Methodology Article

Koning’s machines can reliably detect stage 0 and stage 1 cancers. Just how significant is this? Detecting breast cancer at stages 0 or 1 gives patients a 99% five-year survival rate. Its imaging technology can also detect small calcifications and small tumors in patients with small or dense breasts — something current mammograms struggle with. Calcifications, by the way, are often an early indicator of breast disease.

This changes the game. Mammography has ruled the industry for 60 years. While flawed, it was — for its time — the best technology available. That’s no longer the case. 

Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Koning on StartEngine 2022
Platform: StartEngine
Security Type: Equity - Common
Valuation: $230,180,296
Price per Share: $5.69

Follow company

Follow Koning on StartEngine 2022

Buy Koning's Deal Report

Warning: according to the close date for this deal, Koning may no longer be accepting investments.

Koning Deal Report

Get KingsCrowd’s comprehensive report on Koning including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Koning is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise
  • Our deep-dive analyst report reviewing the deal's investment potential and bullish vs. bearish outlook

Buy the Koning deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge